SG11202002044WA - MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus - Google Patents

MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus

Info

Publication number
SG11202002044WA
SG11202002044WA SG11202002044WA SG11202002044WA SG11202002044WA SG 11202002044W A SG11202002044W A SG 11202002044WA SG 11202002044W A SG11202002044W A SG 11202002044WA SG 11202002044W A SG11202002044W A SG 11202002044WA SG 11202002044W A SG11202002044W A SG 11202002044WA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
mhc class
zika virus
associated peptides
Prior art date
Application number
SG11202002044WA
Other languages
English (en)
Inventor
Ramila Philip
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of SG11202002044WA publication Critical patent/SG11202002044WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202002044WA 2017-09-21 2018-09-21 MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus SG11202002044WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561234P 2017-09-21 2017-09-21
PCT/GB2018/052698 WO2019058133A2 (fr) 2017-09-21 2018-09-21 Peptides associés à la classe i de cmh pour la prévention et le traitement du virus zika

Publications (1)

Publication Number Publication Date
SG11202002044WA true SG11202002044WA (en) 2020-04-29

Family

ID=63708398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002044WA SG11202002044WA (en) 2017-09-21 2018-09-21 MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus

Country Status (6)

Country Link
US (2) US11426457B2 (fr)
EP (1) EP3684405A2 (fr)
BR (1) BR112020005565A2 (fr)
PH (1) PH12020500413A1 (fr)
SG (1) SG11202002044WA (fr)
WO (1) WO2019058133A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021509400A (ja) 2018-01-06 2021-03-25 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ 複数のフラビウイルスの予防および治療を目的としたｍｈｃクラスｉ関連ペプチド
WO2019186200A1 (fr) * 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Compositions de vaccins
BR112020019719A2 (pt) * 2018-03-29 2021-01-26 Emergex Vaccines Holding Limited composições de vacina

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
BR0315935A (pt) 2002-10-31 2005-09-20 Health Research Inc Teste de diagnóstico para o vìrus do nilo ocidental
EP1793863B1 (fr) 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticules contenant un antigene et un adjuvant activant les cellules t auxiliaires
WO2007015105A2 (fr) 2005-08-04 2007-02-08 Thomas William Rademacher Nanoparticules comprenant des ligands antibacteriens
CA2652759C (fr) 2006-04-13 2014-07-08 Midatech Limited Nanoparticules destinees a induire des reponses immunitaires contre des agents infectieux
EP2294192A4 (fr) 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog Compositions et procédés de traitement et de vaccination contre le virus de la dengue (vd)
US9637521B2 (en) * 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
WO2013019658A2 (fr) * 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Nanosupports synthétiques comprenant des polymères comprenant de multiples agents immunomodulateurs
MX345883B (es) 2011-09-07 2017-02-22 Midatech Ltd Composiciones de peptidos en nanoparticulas.
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
WO2017059403A1 (fr) 2015-10-02 2017-04-06 Transocean Sedco Forex Ventures Limited Appareils et procédés permettant de diriger un fluide
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
SG10201913630YA (en) * 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
US11179460B2 (en) * 2017-06-23 2021-11-23 American Type Culture Collection (Atcc) Virus-like particles comprising zika antigen

Also Published As

Publication number Publication date
US11426457B2 (en) 2022-08-30
BR112020005565A2 (pt) 2020-10-06
WO2019058133A2 (fr) 2019-03-28
PH12020500413A1 (en) 2021-03-01
US11931407B2 (en) 2024-03-19
WO2019058133A3 (fr) 2019-05-02
US20200268871A1 (en) 2020-08-27
EP3684405A2 (fr) 2020-07-29
US20230129352A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
SG11202005772YA (en) Mhc class i associated peptides for prevention and treatment of multiple flavi virus
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
HK1248546A1 (zh) Wt1抗原肽和免疫調節劑的組合
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
HK1251616A1 (zh) 用於預防和/或治療感染性疾病以及用於治療腫瘤疾病的減毒流感病毒載體
IL263368A (en) Prevention and treatment of viral infections
EP3468593A4 (fr) Compositions et procédés pour prévenir et traiter l'infection par le virus zika
IL269236A (en) Engineered amphiphilic antimicrobial peptides and methods of use
HK1244201A1 (zh) 芋螺毒素(conotoxin)肽的修飾和用途
IL275550A (en) Recombinant virus on a region reduced from optimal for a codon pair and its use for cancer treatment
ZA201905372B (en) Therapeutic and neuroprotective peptides
SG11202002044WA (en) MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
HK1253377A1 (zh) 可編程的溶瘤病毒疫苗系統及其應用
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
ZA201707110B (en) Recombinant lumpy skin disease virus knock-out mutant and uses thereof
EP3484511A4 (fr) Compositions vaccinales pour le traitement d'une infection par le virus zika
EP3423051A4 (fr) Compositions et procédés de traitement du virus de la grippe
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
GB201615035D0 (en) Treatment and prevention of viral infection
HK1258752A1 (zh) 重組病毒產品及抑制肌球蛋白表達的方法
PL3490604T3 (pl) Środek leczniczy do leczenia i/lub zapobiegania endometriozie
EP3426659A4 (fr) Procédés et compositions pour le traitement d'une infection par le virus zika